IL6 and metabolic dysfunction-associated steatohepatitis: We previously demonstrated that genistein administration prevented liver dysfunction, attenuated NASH progression, and decreased levels of inflammatory factors (TNF-α and IL-6) in plasma and liver of NASH model rats [17].